Despite a less well-characterized ALL organization compared to AML, there are several clinical trials that focus on targeting populations of cells that have a high initiating potential in ALL such as CD34+CD38+CD19+ cells[153]. This evidence concerns the gene CD38 and acute myeloid leukemia.